Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study

Published on January 25, 2022

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

Continue reading on website
Other news

Snowflake Inc. (SNOW) Moves 3.7% Higher: Will This Strength Last?

January 25, 2022
Snowflake Inc. (SNOW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

Here is Why Growth Investors Should Buy Brenntag AG (BNTGY) Now

January 25, 2022
Brenntag AG (BNTGY) possesses solid growth attributes, which could help it handily outperform the market.